期刊文献+

普罗帕酮对“犬”的起搏阈值影响的实验研究 被引量:1

Effect of propafenone on pacing threshold in dogs
下载PDF
导出
摘要 【目的】观察逐步加大普罗帕酮剂量后对起搏阈值、感知和电极阻抗的影响。【方法】动物(犬,n=12)麻醉后,维持自主呼吸。放置心房和心室起搏电极后,静脉给予不同剂量的普罗帕酮,比较用药前后起搏阈值、感知和电极阻抗以及血压、心率等参数的变化。普罗帕酮剂量依次是3.1、3.1、4.65、4.65 mg/kg和6.2mg/kg。每次用药后5 min测定上述指标,并采用高效液相色谱法测定普罗帕酮的血清浓度。【结果】普罗帕酮剂量增至6.2 mg/kg时,心房起搏阈值从(0.98±0.36)V增加至(8.25±1.92)V(P<0.01),增加幅度与普罗帕酮血清浓度呈正相关,r=0.826,P=0.029。心室起搏阈值从(0.55±0.35)V增加至(2.30±1.78)V(P<0.01),增加幅度与普罗帕酮血清浓度无明显相关,r=0.375,P=0.265。P波振幅从(4.8±1.3)mV降至(1.6±0.7)mV(P<0.01),R波振幅从20mV降至(18.3±2.2)mV,(P<0.05)。平均动脉压(MBP)从(142±11)mmHg降至(67±12)mmHg,心率从(163±13)降至(90±10)次/min,(均为P<0.01)。PR间期从(98±10)ms延长至(159±28)ms,QRS间期从(40±5)ms至(102±22)ms,QTc间期从(315±32)ms至(366±18)ms,(均为P<0.01)。【结论】随着普罗帕酮剂量逐渐增加,起搏阈值明显增加,心房起搏阈值尤其明显。 [ Objective ] To increase the doses of propafenone gradually and observe the effect of propafenone on the pacing threshold at larger doses. [Methods] The experiment was performed in 12 adult mongrel dogs weighting 14.21 ± 1.98 kg (13- 17 kg) . Under general anesthesia with intravenous barbital sodium (30 mg/kg), two electrical catheters were inserted into the right atrium and the right ventricle through jugular vein, respectively. The basic atrial and ventricular pacing threshold, sensing threshold and lead impedance, blood pressure, heart rate (HR), PR interval, QRS duration and QTc interval were obtained. Propafenone were intravenously administered in different doses (3.1, 3.1, 4.65, 4.65 mg/kg and 6.2 mg/kg) during a 20- minute period. After drugs, the parameters above were determined repeatedly. The serum concentrations of prepafenone were determined by high performance liquid chromatography. [Results] When prepafenone reached a dose of 6.2 mg/kg, Atrial and ventricular pacing threshold increased from ( 0.98± 0.36 ) V to (8.25 ±1.92 ) V and (0.55 ± 0.35) V to (2.30 ± 1.78) V, respectively (all P 〈 0.01) . P or R amplitude decreased from (4.8 ± 1.3) mV to (1.6±0.7) mV (P 〈 0.01) and 20mV to (18.3 ±2.2) mV (P〈0.05), respectively. MBP and HR decreased from (142± 11) mmHg to (67± 12) mmHg and (163±13) bpm to (90 ± 10) bpm, respectively (allP 〈 0.01), compared with the baseline. PR interval, QRS duration and QTc interval prolonged from (98±10) ms to (159±28) ms, (40±5) ms to (102±22) ms, (315±32) ms to (366±18) ms, respeetively (all P 〈 0.01 ) . [ Conclusions] With increasing of propafenone doses, MBP and HR decreased, and PR interval, QRS duration and QTc interval prolonged. Atrial pacing threshold incresed much more than ventricular pacing threshold following intravenous propafenone administration.
出处 《武警医学院学报》 CAS 2009年第5期396-399,共4页 Acta Academiae Medicinae CPAPF
关键词 抗心律失常药物 起搏阈值 电生理指标 血清药物浓度 Antiarrhythmics Pacing thresholds Electrophysiological parameters serum drug concentrations
  • 相关文献

参考文献10

  • 1Myerburg P,J,Kesserler KM,Castellanon A.Sudden cardiac death:function,and time-dependence of risk[J].Circulation,1992,85(Suppl I):2-10
  • 2董军亚,张继红,焦晓红,焦建杰,黄体钢.高效液相色谱法测定人血清中普罗帕酮的浓度[J].武警医学,2006,17(6):427-429. 被引量:6
  • 3Liberss S,Caron J,Pladys A,et al.Propafenone versus disopyramide:a double-blind randomized crossover trial in patients presenting chronic ventricular arrhythmias[J].J Clin Cardiol,1987,10:405 -410.
  • 4Zobel RG,Kirsten EB,Brewington J.Pharmacokinetic and piarmacotynamic evaluation of propafenone in patients with ventricular arrhythmia[J].Clin Pharm Therap,1989,45:535-541.
  • 5Schuchert A,Meinertz T.Acute effects of a Class Ⅰ a antiarrhythmic drug on the ventricular evoked response amplitude in patients with cardiac pacemakers[J].Cardiology,2000,94(5):103-105.
  • 6Numata T,Abe H,Nagatomo T,et al.Ventricular pacing failure after a single oral dose pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation[J].PACE,2000,23(9):1436-1438.
  • 7Creamer JE,Nathan Aw,Shennan A,et al.Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constantrate pacing[J].Am J Cardiol,1986,57(13):1092-1096.
  • 8Santini M,Pignalberi C,Ricci R,et al.Effectivenedd of ibutilide in cardioversion of persistent atrial fibrillation in patients with dual chamber stimulation[J].J Interv Card Electrophysiol,2003,9(1):15-20.
  • 9Montefoshi N,Boccadamo R.Propafenone induced acute variation of chronic atrial pacing threshold:a case report[J].PACE,1990,13(4):480-483.
  • 10方全,郭涛,Jackson K,Lieberman R.心脏三腔起搏除颤器的临床应用[J].中华心血管病杂志,2005,33(1):22-25. 被引量:11

二级参考文献15

  • 1Desai AD, Liem LB, Chun SH, et al. Accuracy of the Ritter method in determining optimal atrio-ventricular delay in patients undergoing cardiac resynchronization therapy for congestive heart failure. PACE,2001,24(Part II):665.
  • 2Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation,2000,102:3053-3059.
  • 3Beanlands RS, Bach DS, Raylman R, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measure using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol,1993,22:1389-1398.
  • 4Hasenfuss G, Holubarsch C, Heiss HW, et al. Myocardial energetics in patients with dilated cardiomyopathy: influence of nitroprusside and enoximone. Circulation,1989,80:51-64.
  • 5Hasenfuss G, Holubarsch C, Heiss HW, et al. Influence of enoximone on myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside. J Cardiovasc Pharmacol,1989,14:S69-S74.
  • 6Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol,1994,24:1310-1320.
  • 7Bardy GH. SCD-HeFT. The sudden cardiac death in heart failure trial. The American College of Cardiology Annual Scientific Session. New Orleans, March 8, 2004.
  • 8Young JB, Abranham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. JAMA,2003,289:2685-2694.
  • 9Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol ,2003,42:1454-1459.
  • 10余琛,张慧,洪有采,任建英,杨露芳,仇兴标,李志善.普罗帕酮在心律失常患者中的代谢[J].中国临床药学杂志,1998,7(6):261-264. 被引量:2

共引文献15

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部